Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial Letter

sustainable development goals

publication date

  • February 1, 2023

webpage

published in

keywords

  • ADVANCE
  • apremilast
  • clinical trial
  • long-term
  • mild-to-moderate psoriasis
  • pruritus
  • quality of life
  • scalp

start page

  • 430

end page

  • 433

volume

  • 88

issue

  • 2